MSB 3.21% $1.13 mesoblast limited

2024 Here we go again., page-588

  1. 2,891 Posts.
    lightbulb Created with Sketch. 2048
    Thx imback- smaller less expensive trial to get the label expanded to adults.

    I think it was @omnisearch who came up with total patient numbers under 70?

    Smaller trial costing less and presumably a much shorter time to recruit fits with not proceeding at this time.

    Still, spending ten million of available cash indicates supreme confidence.

    My personal opinion

    Reg




 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.